Claims
- 1. A method for establishing a signature profile indicative of the physiological status of an individual, comprising:
a) entering a unique identifier of at least one biological sample into a computer tracking system; b) storing in said computer tracking system data from said biological sample, wherein said data are linked to said unique identifier; c) converting said linked data to a numeric format; d) converting said numeric format data to a common unit system, wherein said common unit system data is a coherent data set; and e) determining the most informative of said common unit system data; wherein said most informative data are a signature profile indicative of physiological status.
- 2. The method according to claim 1, wherein the computer tracking system is a Laboratory Information Management System (LIMS).
- 3. The method according to claim 1, wherein the biological sample is selected from the group consisting of animalia, plantae, protista, monera, and fungi.
- 4. The method according to claim 3, wherein the biological sample is selected from the group consisting of human primate, non-human primate, canine, feline, equine, bovine, porcine, rabbit, rodent, liver tissue, liver spheroids, primary hepatocytes, liver cell lines, and HepG2 cells.
- 5. The method according to claim 3, wherein the biological sample is selected from the group consisting of Arabidopsis, corn, wheat, barley, rye, legumes, mint, tobacco, tomatoes, rice, spinach, and peas.
- 6. The method according to claim 3, wherein the biological sample is selected from the group consisting of Magnaporthe, Candida, Mycosphaerella, Botrytis, Saccharomyces, Aspergillus, Puccinia, Erysiphe, Ustilago, Fursarium, Phytophthora and Penicillium.
- 7. The method according to claim 1, wherein said signature profile is indicative of a particular disease or disease stage.
- 8. The method according to claim 1, wherein said signature profile is indicative of the efficacy of a therapeutic program or exposure to a particular chemical.
- 9. The method according to claim 1, wherein the biological sample is selected from the group consisting of a healthy organism, a diseased organism, a drug-treated organism, and a genetically altered organism.
- 10. The method according to claim 1, wherein the biological sample is from an organism having received an environmental or chemical insult.
- 11. The method according to claim 1, wherein the common unit system is deviation from a standard.
- 12. A method for establishing a signature profile indicative of the physiological status of an individual, comprising:
a) entering a unique identifier of at least one biological sample into a computer tracking system; b) storing in said computer tracking system data from said biological sample, wherein said data are linked to said unique identifier; c) converting said linked data to a numeric format; d) transforming said numeric format data into a Gaussian distribution; e) converting said Gaussian distribution data to a common unit system; f) reducing the dimensionality of said common unit system data, wherein said dimensionally reduced common unit system data is a coherent data set; and g) determining the most informative of said dimensionally reduced common unit system data; wherein said most informative data are a signature profile indicative of physiological status.
- 13. The method according to claim 12, wherein the computer tracking system is a Laboratory Information Management System (LIMS).
- 14. The method according to claim 12, wherein the biological sample is selected from the group consisting of animalia, plantae, protista, monera, and fungi.
- 15. The method according to claim 14, wherein the biological sample is selected from the group consisting of human primate, non-human primate, canine, feline, equine, bovine, porcine, rabbit, rodent, liver tissue, liver spheroids, primary hepatocytes, liver cell lines, and HepG2 cells.
- 16. The method according to claim 14, wherein the biological sample is selected from the group consisting of Arabidopsis, corn, wheat, barley, rye, legumes, mint, tobacco, tomatoes, rice, spinach, and peas.
- 17. The method according to claim 14, wherein the biological sample is selected from the group consisting of Magnaporthe, Candida, Mycosphaerella, Botrytis, Saccharomyces, Aspergillus, Puccinia, Erysiphe, Ustilago, Fursarium, Phytophthora and Penicillium.
- 18. The method according to claim 12, wherein said signature profile is indicative of a particular disease or disease stage.
- 19. The method according to claim 12, wherein said signature profile is indicative of the efficacy of a therapeutic program or exposure to a particular chemical.
- 20. The method according to claim 12, wherein the biological sample is selected from the group consisting of a healthy organism, a diseased organism, a drug-treated organism, and a genetically altered organism.
- 21. The method according to claim 12, wherein the biological sample is from an organism having received an environmental or chemical insult.
- 22. The method according to claim 12, wherein the common unit system is deviation from a standard.
- 23. The method according to claim 12, wherein said reduction of dimensionality is achieved by applying one of the group consisting of principle components analysis, correlation analysis, regression analysis, and pre-clustering of said common unit system data.
- 24. The method according to claim 12, wherein said transformation into a Gaussian distribution occurs by conversion of said numeric format data to a logarithmic scale.
- 25. A method for establishing a signature profile indicative of the physiological status of an individual, comprising:
a) entering a unique identifier of at least one biological sample into a computer tracking system; b) storing in said computer tracking system data from said biological sample, wherein said data are linked to said unique identifier; c) converting said linked data to a numeric format; d) transforming said numeric format data into a Gaussian distribution; e) converting said Gaussian distribution data to a common unit system wherein said common unit system data is a coherent data set; and f) determining the most informative of said common unit system data; wherein said most informative data are a signature profile indicative of physiological status.
- 26. The method according to claim 25, wherein the computer tracking system is a Laboratory Information Management System (LIMS).
- 27. The method according to claim 25, wherein the biological sample is selected from the group consisting of animalia, plantae, protista, monera, and fungi.
- 28. The method according to claim 27, wherein the biological sample is selected from the group consisting of human primate, non-human primate, canine, feline, equine, bovine, porcine, rabbit, rodent, liver tissue, liver spheroids, primary hepatocytes, liver cell lines, and HepG2 cells.
- 29. The method according to claim 27, wherein the biological sample is selected from the group consisting of Arabidopsis, corn, wheat, barley, rye, legumes, mint, tobacco, tomatoes, rice, spinach, and peas.
- 30. The method according to claim 27, wherein the biological sample is selected from the group consisting of Magnaporthe, Candida, Mycosphaerella, Botrytis, Saccharomyces, Aspergillus, Puccinia, Erysiphe, Ustilago, Fursarium, Phytophthora and Penicillium.
- 31. The method according to claim 25, wherein said signature profile is indicative of a particular disease or disease stage.
- 32. The method according to claim 25, wherein said signature profile is indicative of the efficacy of a therapeutic program or exposure to a particular chemical.
- 33. The method according to claim 25, wherein the biological sample is selected from the group consisting of a healthy organism, a diseased organism, a drug-treated organism, and a genetically altered organism.
- 34. The method according to claim 25, wherein the biological sample is from an organism having received an environmental or chemical insult.
- 35. The method according to claim 25, wherein the common unit system is deviation from a standard.
- 36. The method according to claim 25, wherein said transformation into a Gaussian distribution occurs by conversion of said numeric format data to a logarithmic scale.
- 37. A method for establishing a signature profile indicative of the physiological status of an individual, comprising:
a) entering a unique identifier of at least one biological sample into a computer tracking system; b) storing in said computer tracking system data from said biological sample, wherein said data are linked to said unique identifier; c) converting said linked data to a numeric format; d) converting said numeric format data to a common unit system; e) reducing the dimensionality of said common unit system data, wherein said dimensionally reduced data is a coherent data set; and f) determining the most informative of said dimensionally reduced data; wherein said most informative data are a signature profile indicative of physiological status.
- 38. The method according to claim 37, wherein the computer tracking system is a Laboratory Information Management System (LIMS).
- 39. The method according to claim 37, wherein the biological sample is selected from the group consisting of animalia, plantae, protista, monera, and fungi.
- 40. The method according to claim 39, wherein the biological sample is selected from the group consisting of human primate, non-human primate, canine, feline, equine, bovine, porcine, rabbit, rodent, liver tissue, liver spheroids, primary hepatocytes, liver cell lines, and HepG2 cells.
- 41. The method according to claim 39, wherein the biological sample is selected from the group consisting of Arabidopsis, corn, wheat, barley, rye, legumes, mint, tobacco, tomatoes, rice, spinach, and peas.
- 42. The method according to claim 39, wherein the biological sample is selected from the group consisting of Magnaporthe, Candida, Mycosphaerella, Botrytis, Saccharomyces, Aspergillus, Puccinia, Erysiphe, Ustilago, Fursarium, Phytophthora and Penicillium.
- 43. The method according to claim 37, wherein said signature profile is indicative of a particular disease or disease stage.
- 44. The method according to claim 37, wherein said signature profile is indicative of the efficacy of a therapeutic program or exposure to a particular chemical.
- 45. The method according to claim 37, wherein the biological sample is selected from the group consisting of a healthy organism, a diseased organism, a drug-treated organism, and a genetically altered organism.
- 46. The method according to claim 37, wherein the biological sample is from an organism having received an environmental or chemical insult.
- 47. The method according to claim 37, wherein the common unit system is deviation from a standard.
- 48. The method according to claim 37, wherein said reduction of dimensionality is achieved by applying one of the group consisting of principle components analysis, correlation analysis, regression analysis, and pre-clustering of said common unit system data.
- 49. A method for establishing a signature profile indicative of the physiological status of an individual, comprising:
a) entering a unique identifier of at least one biological sample into a computer tracking system; b) storing in said computer tracking system disparate data, wherein said disparate data comprise at least two types of data and said disparate data are linked to said unique identifier; c) converting said linked disparate data to a numeric format; d) converting said numeric format data to a common unit system, wherein said common unit system data is a coherent data set; and e) determining the most informative of said common unit system data; wherein said most informative data are a signature profile indicative of physiological status.
- 50. The method according to claim 49, wherein said at least two types of data are obtained from the group consisting of RNA data, DNA data, protein data, metabolite data, and phenotypic data.
- 51. The method according to claim 49, wherein the computer tracking system is a Laboratory Information Management System (LIMS).
- 52. The method according to claim 49, wherein the biological sample is selected from the group consisting of animalia, plantae, protista, monera, and fungi.
- 53. The method according to claim 52, wherein the biological sample is selected from the group consisting of human primate, non-human primate, canine, feline, equine, bovine, porcine, rabbit, rodent, liver tissue, liver spheroids, primary hepatocytes, liver cell lines, and HepG2 cells.
- 54. The method according to claim 52, wherein the biological sample is selected from the group consisting of Arabidopsis, corn, wheat, barley, rye, legumes, mint, tobacco, tomatoes, rice, spinach, and peas.
- 55. The method according to claim 52, wherein the biological sample is selected from the group consisting of Magnaporthe, Candida, Mycosphaerella, Botrytis, Saccharomyces, Aspergillus, Puccinia, Erysiphe, Ustilago, Fursarium, Phytophthora and Penicillium.
- 56. The method according to claim 49, wherein said signature profile is indicative of a particular disease or disease stage.
- 57. The method according to claim 49, wherein said signature profile is indicative of the efficacy of a therapeutic program or exposure to a particular chemical.
- 58. The method according to claim 49, wherein the biological sample is selected from the group consisting of a healthy organism, a diseased organism, a drug-treated organism, and a genetically altered organism.
- 59. The method according to claim 49, wherein the biological sample is from an organism having received an environmental or chemical insult.
- 60. The method according to claim 49, wherein the common unit system is deviation from a standard.
- 61. A method for establishing a signature profile indicative of the physiological status of an individual, comprising:
a) entering a unique identifier of at least one biological sample into a computer tracking system; b) storing in said computer tracking system disparate data, wherein said disparate data comprise at least two types of data and said disparate data are linked to said unique identifier; c) converting said linked disparate data to a numeric format; d) transforming said numeric format data into a Gaussian distribution; e) converting said Gaussian distribution data to a common unit system; f) reducing the dimensionality of said common unit system data, wherein said dimensionally reduced data is a coherent data set; and g) determining the most informative of said dimensionally reduced data; wherein said most informative data are a signature profile indicative of physiological status.
- 62. The method according to claim 61, wherein said at least two types of data are obtained from the group consisting of RNA data, DNA data, protein data, metabolite data, and phenotypic data.
- 63. The method according to claim 61, wherein the computer tracking system is a Laboratory Information Management System (LIMS).
- 64. The method according to claim 61, wherein the biological sample is selected from the group consisting of animalia, plantae, protista, monera, and fungi.
- 65. The method according to claim 64, wherein the biological sample is selected from the group consisting of human primate, non-human primate, canine, feline, equine, bovine, porcine, rabbit, rodent, liver tissue, liver spheroids, primary hepatocytes, liver cell lines, and HepG2 cells.
- 66. The method according to claim 64, wherein the biological sample is selected from the group consisting of Arabidopsis, corn, wheat, barley, rye, legumes, mint, tobacco, tomatoes, rice, spinach, and peas.
- 67. The method according to claim 64, wherein the biological sample is selected from the group consisting of Magnaporthe, Candida, Mycosphaerella, Botrytis, Saccharomyces, Aspergillus, Puccinia, Erysiphe, Ustilago, Fursarium, Phytophthora and Penicillium.
- 68. The method according to claim 61, wherein said signature profile is indicative of a particular disease or disease stage.
- 69. The method according to claim 61, wherein said signature profile is indicative of the efficacy of a therapeutic program or exposure to a particular chemical.
- 70. The method according to claim 61, wherein the biological sample is selected from the group consisting of a healthy organism, a diseased organism, a drug-treated organism, and a genetically altered organism.
- 71. The method according to claim 61, wherein the biological sample is from an organism having received an environmental or chemical insult.
- 72. The method according to claim 61, wherein the common unit system is deviation from a standard.
- 73. The method according to claim 61, wherein said reduction of dimensionality is achieved by applying one of the group consisting of principle components analysis, correlation analysis, regression analysis, and pre-clustering of said common unit system data.
- 74. The method according to claim 61, wherein said transformation into a Gaussian distribution occurs by conversion of said numeric format data to a logarithmic scale.
- 75. A method for establishing a signature profile indicative of the physiological status of an individual, comprising:
a) entering a unique identifier of at least one biological sample into a computer tracking system; b) storing in said computer tracking system disparate data, wherein said disparate data comprise at least two types of data and said disparate data are linked to said unique identifier; c) converting said linked disparate data to a numeric format; d) converting said numeric format data to a common unit system; e) reducing the dimensionality of said common unit system data, wherein said dimensionally reduced data is a coherent data set; and f) determining the most informative of said dimensionally reduced data; wherein said most informative data are a signature profile indicative of physiological status.
- 76. The method according to claim 75, wherein said at least two types of data are obtained from the group consisting of RNA data, DNA data, protein data, metabolite data, and phenotypic data.
- 77. The method according to claim 75, wherein the computer tracking system is a Laboratory Information Management System (LIMS).
- 78. The method according to claim 75, wherein the biological sample is selected from the group consisting of animalia, plantae, protista, monera, and fungi.
- 79. The method according to claim 78, wherein the biological sample is selected from the group consisting of human primate, non-human primate, canine, feline, equine, bovine, porcine, rabbit, rodent, liver tissue, liver spheroids, primary hepatocytes, liver cell lines, and HepG2 cells.
- 80. The method according to claim 78, wherein the biological sample is selected from the group consisting of Arabidopsis, corn, wheat, barley, rye, legumes, mint, tobacco, tomatoes, rice, spinach, and peas.
- 81. The method according to claim 78, wherein the biological sample is selected from the group consisting of Magnaporthe, Candida, Mycosphaerella, Botrytis, Saccharomyces, Aspergillus, Puccinia, Erysiphe, Ustilago, Fursarium, Phytophthora and Penicillium.
- 82. The method according to claim 75, wherein said signature profile is indicative of a particular disease or disease stage.
- 83. The method according to claim 75, wherein said signature profile is indicative of the efficacy of a therapeutic program or exposure to a particular chemical.
- 84. The method according to claim 75, wherein the biological sample is selected from the group consisting of a healthy organism, a diseased organism, a drug-treated organism, and a genetically altered organism.
- 85. The method according to claim 75, wherein the biological sample is from an organism having received an environmental or chemical insult.
- 86. The method according to claim 75, wherein the common unit system is deviation from a standard.
- 87. The method according to claim 75, wherein said reduction of dimensionality is achieved by applying one of the group consisting of principle components analysis, correlation analysis, regression analysis, and pre-clustering of said common unit system data.
- 88. A method for establishing a signature profile indicative of the physiological status of an individual, comprising:
a) entering a unique identifier of at least one biological sample into a computer tracking system; b) storing in said computer tracking system disparate data, wherein said disparate data comprise at least two types of data and said disparate data are linked to said unique identifier; c) converting said linked disparate data to a numeric format; d) transforming said numeric format data into a Gaussian distribution; e) converting said Gaussian distribution data to a common unit system, wherein said common unit system data is a coherent data set; and f) determining the most informative of said common unit system data; wherein said most informative data are a signature profile indicative of physiological status.
- 89. The method according to claim 88, wherein said at least two types of data are obtained from the group consisting of RNA data, DNA data, protein data, metabolite data, and phenotypic data.
- 90. The method according to claim 88, wherein the computer tracking system is a Laboratory Information Management System (LIMS).
- 91. The method according to claim 88, wherein the biological sample is selected from the group consisting of animalia, plantae, protista, monera, and fungi.
- 92. The method according to claim 91, wherein the biological sample is selected from the group consisting of human primate, non-human primate, canine, feline, equine, bovine, porcine, rabbit, rodent, liver tissue, liver spheroids, primary hepatocytes, liver cell lines, and HepG2 cells.
- 93. The method according to claim 91, wherein the biological sample is selected from the group consisting of Arabidopsis, corn, wheat, barley, rye, legumes, mint, tobacco, tomatoes, rice, spinach, and peas.
- 94. The method according to claim 91, wherein the biological sample is selected from the group consisting of Magnaporthe, Candida, Mycosphaerella, Botrytis, Saccharomyces, Aspergillus, Puccinia, Erysiphe, Ustilago, Fursarium, Phytophthora and Penicillium.
- 95. The method according to claim 88, wherein said signature profile is indicative of a particular disease or disease stage.
- 96. The method according to claim 88, wherein said signature profile is indicative of the efficacy of a therapeutic program or exposure to a particular chemical.
- 97. The method according to claim 88, wherein the biological sample is selected from the group consisting of a healthy organism, a diseased organism, a drug-treated organism, and a genetically altered organism.
- 98. The method according to claim 88, wherein the biological sample is from an organism having received an environmental or chemical insult.
- 99. The method according to claim 88, wherein the common unit system is deviation from a standard.
- 100. The method according to claim 88, wherein said transformation into a Gaussian distribution occurs by conversion of said numeric format data to a logarithmic scale.
- 101. A method for establishing a signature profile indicative of the physiological status of an individual, comprising:
a) entering a unique identifier of at least one biological sample into a computer tracking system; b) storing in said computer tracking system disparate data, wherein said disparate data comprise at least three types of data and said disparate data are linked to said unique identifier; c) converting said linked disparate data to a numeric format; d) converting said numeric format data to a common unit system, wherein said common unit system data is a coherent data set; and e) determining the most informative of said common unit system data; wherein said most informative data are a signature profile indicative of physiological status.
- 102. The method according to claim 101, wherein said at least three types of data are obtained from the group consisting of RNA data, DNA data, protein data, metabolite data, and phenotypic data.
- 103. The method according to claim 101, wherein the computer tracking system is a Laboratory Information Management System (LIMS).
- 104. The method according to claim 101, wherein the biological sample is selected from the group consisting of animalia, plantae, protista, monera, and fungi.
- 105. The method according to claim 104, wherein the biological sample is selected from the group consisting of human primate, non-human primate, canine, feline, equine, bovine, porcine, rabbit, rodent, liver tissue, liver spheroids, primary hepatocytes, liver cell lines, and HepG2 cells.
- 106. The method according to claim 104, wherein the biological sample is selected from the group consisting of Arabidopsis, corn, wheat, barley, rye, legumes, mint, tobacco, tomatoes, rice, spinach, and peas.
- 107. The method according to claim 104, wherein the biological sample is selected from the group consisting of Magnaporthe, Candida, Mycosphaerella, Botrytis, Saccharomyces, Aspergillus, Puccinia, Erysiphe, Ustilago, Fursarium, Phytophthora and Penicillium.
- 108. The method according to claim 101, wherein said signature profile is indicative of a particular disease or disease stage.
- 109. The method according to claim 101, wherein said signature profile is indicative of the efficacy of a therapeutic program or exposure to a particular chemical.
- 110. The method according to claim 101, wherein the biological sample is selected from the group consisting of a healthy organism, a diseased organism, a drug-treated organism, and a genetically altered organism.
- 111. The method according to claim 101, wherein the biological sample is from an organism having received an environmental or chemical insult.
- 112. The method according to claim 101, wherein the common unit system is deviation from a standard.
- 113. A method for establishing a signature profile indicative of the physiological status of an individual, comprising:
a) entering a unique identifier of at least one biological sample into a computer tracking system; b) storing in said computer tracking system disparate data, wherein said disparate data comprise at least three types of data and said disparate data are linked to said unique identifier; c) converting said linked disparate data to a numeric format; d) transforming said numeric format data into a Gaussian distribution; e) converting said Gaussian distribution data to a common unit system; f) reducing the dimensionality of said common unit system data, wherein said dimensionally reduced data is a coherent data set; and g) determining the most informative of said dimensionally reduced data; wherein said most informative data are a signature profile indicative of physiological status.
- 114. The method according to claim 113, wherein said at least three types of data are obtained from the group consisting of RNA data, DNA data, protein data, metabolite data, and phenotypic data.
- 115. The method according to claim 113, wherein the computer tracking system is a Laboratory Information Management System (LIMS).
- 116. The method according to claim 113, wherein the biological sample is selected from the group consisting of animalia, plantae, protista, monera, and fungi.
- 117. The method according to claim 116, wherein the biological sample is selected from the group consisting of human primate, non-human primate, canine, feline, equine, bovine, porcine, rabbit, rodent, liver tissue, liver spheroids, primary hepatocytes, liver cell lines, and HepG2 cells.
- 118. The method according to claim 116, wherein the biological sample is selected from the group consisting of Arabidopsis, corn, wheat, barley, rye, legumes, mint, tobacco, tomatoes, rice, spinach, and peas.
- 119. The method according to claim 116, wherein the biological sample is selected from the group consisting of Magnaporthe, Candida, Mycosphaerella, Botrytis, Saccharomyces, Aspergillus, Puccinia, Erysiphe, Ustilago, Fursarium, Phytophthora and Penicillium.
- 120. The method according to claim 113, wherein said signature profile is indicative of a particular disease or disease stage.
- 121. The method according to claim 113, wherein said signature profile is indicative of the efficacy of a therapeutic program or exposure to a particular chemical.
- 122. The method according to claim 113, wherein the biological sample is selected from the group consisting of a healthy organism, a diseased organism, a drug-treated organism, and a genetically altered organism.
- 123. The method according to claim 113, wherein the biological sample is from an organism having received an environmental or chemical insult.
- 124. The method according to claim 113, wherein the common unit system is deviation from a standard.
- 125. The method according to claim 113, wherein said reduction of dimensionality is achieved by applying one of the group consisting of principle components analysis, correlation analysis, regression analysis, and pre-clustering of said common unit system data.
- 126. The method according to claim 113, wherein said transformation into a Gaussian distribution occurs by conversion of said numeric format data to a logarithmic scale.
- 127. A method for establishing a signature profile indicative of the physiological status of an individual, comprising:
a) entering a unique identifier of at least one biological sample into a computer tracking system; b) storing in said computer tracking system disparate data, wherein said disparate data comprise at least three types of data and said disparate data are linked to said unique identifier; c) converting said linked disparate data to a numeric format; d) converting said numeric format data to a common unit system; e) reducing the dimensionality of said common unit system data, wherein said dimensionally reduced common unit system data is a coherent data set; and f) determining the most informative of said dimensionally reduced data; wherein said most informative data are a signature profile indicative of physiological status.
- 128. The method according to claim 127, wherein said at least three types of data are obtained from the group consisting of RNA data, DNA data, protein data, metabolite data, and phenotypic data.
- 129. The method according to claim 127, wherein the computer tracking system is a Laboratory Information Management System (LIMS).
- 130. The method according to claim 127, wherein the biological sample is selected from the group consisting of animalia, plantae, protista, monera, and fungi.
- 131. The method according to claim 130, wherein the biological sample is selected from the group consisting of human primate, non-human primate, canine, feline, equine, bovine, porcine, rabbit, rodent, liver tissue, liver spheroids, primary hepatocytes, liver cell lines, and HepG2 cells.
- 132. The method according to claim 130, wherein the biological sample is selected from the group consisting of Arabidopsis, corn, wheat, barley, rye, legumes, mint, tobacco, tomatoes, rice, spinach, and peas.
- 133. The method according to claim 130, wherein the biological sample is selected from the group consisting of Magnaporthe, Candida, Mycosphaerella, Botrytis, Saccharomyces, Aspergillus, Puccinia, Erysiphe, Ustilago, Fursarium, Phytophthora and Penicillium.
- 134. The method according to claim 127, wherein said signature profile is indicative of a particular disease or disease stage.
- 135. The method according to claim 127, wherein said signature profile is indicative of the efficacy of a therapeutic program or exposure to a particular chemical.
- 136. The method according to claim 127, wherein the biological sample is selected from the group consisting of a healthy organism, a diseased organism, a drug-treated organism, and a genetically altered organism.
- 137. The method according to claim 127, wherein the biological sample is from an organism having received an environmental or chemical insult.
- 138. The method according to claim 127, wherein the common unit system is deviation from a standard.
- 139. The method according to claim 127, wherein said reduction of dimensionality is achieved by applying one of the group consisting of principle components analysis, correlation analysis, regression analysis, and pre-clustering of said common unit system data.
- 140. A method for establishing a signature profile indicative of the physiological status of an individual, comprising:
a) entering a unique identifier of at least one biological sample into a computer tracking system; b) storing in said computer tracking system disparate data, wherein said disparate data comprise at least three types of data and said disparate data are linked to said unique identifier; c) converting said linked disparate data to a numeric format; d) transforming said numeric format data into a Gaussian distribution; e) converting said Gaussian distribution data to a common unit system, wherein said common unit system data is a coherent data set; and f) determining the most informative of said common unit system data; wherein said most informative data are a signature profile indicative of physiological status.
- 141. The method according to claim 140, wherein said at least three types of data are obtained from the group consisting of RNA data, DNA data, protein data, metabolite data, and phenotypic data.
- 142. The method according to claim 140, wherein the computer tracking system is a Laboratory Information Management System (LIMS).
- 143. The method according to claim 140, wherein the biological sample is selected from the group consisting of animalia, plantae, protista, monera, and fungi.
- 144. The method according to claim 143, wherein the biological sample is selected from the group consisting of human primate, non-human primate, canine, feline, equine, bovine, porcine, rabbit, rodent, liver tissue, liver spheroids, primary hepatocytes, liver cell lines, and HepG2 cells.
- 145. The method according to claim 143, wherein the biological sample is selected from the group consisting of Arabidopsis, corn, wheat, barley, rye, legumes, mint, tobacco, tomatoes, rice, spinach, and peas.
- 146. The method according to claim 143, wherein the biological sample is selected from the group consisting of Magnaporthe, Candida, Mycosphaerella, Botrytis, Saccharomyces, Aspergillus, Puccinia, Erysiphe, Ustilago, Fursarium, Phytophthora and Penicillium.
- 147. The method according to claim 140, wherein said signature profile is indicative of a particular disease or disease stage.
- 148. The method according to claim 140, wherein said signature profile is indicative of the efficacy of a therapeutic program or exposure to a particular chemical.
- 149. The method according to claim 140, wherein the biological sample is selected from the group consisting of a healthy organism, a diseased organism, a drug-treated organism, and a genetically altered organism.
- 150. The method according to claim 140, wherein the biological sample is from an organism having received an environmental or chemical insult.
- 151. The method according to claim 140, wherein the common unit system is deviation from a standard.
- 152. The method according to claim 140, wherein said transformation into a Gaussian distribution occurs by conversion of said numeric format data to a logarithmic scale.
RELATED APPLICATIONS
[0001] This application claims the benefit of U.S. Provisional Application No. 60/414,488, filed Sep. 27, 2002; U.S. Provisional Application No. 60/408,721, filed Sep. 6, 2002; U.S. Provisional Application No. 60/407,840, filed Sep. 3, 2002; U.S. Provisional Application No. 60/404,233, filed Aug. 16, 2002; U.S. Provisional Application No. 60/384,445, filed May 30, 2002; U.S. Provisional Application No. 60/379,562, filed May 10, 2002; U.S. Provisional Application No. 60/374,229, filed Apr. 19, 2002; U.S. Provisional Application No. 60/372,679, filed Apr. 15, 2002; U.S. Provisional Application No. 60/368,776, filed Mar. 29, 2002; U.S. Provisional Application No. 60/363,685, filed Mar. 12, 2002; U.S. Provisional Application No. 60/356,994, filed Feb. 14, 2002; U.S. Provisional Application No. 60/344,953, filed Dec. 21, 2001; and U.S. Provisional Application No. 60/331,948, filed Nov. 21, 2001. All of the foregoing patent applications are incorporated in their entirety by reference.
[0002] The present application is related to U.S. application Ser. No. ______, filed Nov. 20, 2002, titled “Methods and Systems for Analyzing Complex Biological Systems” (Attorney Docket Number 2114US1); U.S. application Ser. No. ______, filed Nov. 20, 2002, titled “Methods and Systems for Analyzing Complex Biological Systems” (Attorney Docket Number 2114US2); U.S. application Ser. No. ______, filed Nov. 20, 2002, titled “Methods and Systems for Analyzing Complex Biological Systems” (Attorney Docket Number 2114US3); U.S. application Ser. No. ______, filed Nov. 20, 2002, titled “Methods and Systems for Analyzing Complex Biological Systems” (Attorney Docket Number 2114US4); U.S. application Ser. No. ______, filed Nov. 20, 2002, titled “Methods and Systems for Analyzing Complex Biological Systems” (Attorney Docket Number 2114US6); U.S. application Ser. No. ______, filed Nov. 20, 2002, titled “Methods and Systems for Analyzing Complex Biological Systems” (Attorney Docket Number 2114US7); U.S. application Ser. No. ______, filed Nov. 20, 2002, titled “Methods and Systems for Analyzing Complex Biological Systems” (Attorney Docket Number 2114US8); U.S. application Ser. No. ______, filed Nov. 20, 2002, titled “Methods and Systems for Analyzing Complex Biological Systems” (Attorney Docket Number 2114US9); and U.S. application Ser. No. ______, filed Nov. 20, 2002, titled “Methods and Systems for Analyzing Complex Biological Systems” (Attorney Docket Number 2114US 10).
Provisional Applications (13)
|
Number |
Date |
Country |
|
60414488 |
Sep 2002 |
US |
|
60408721 |
Sep 2002 |
US |
|
60407840 |
Sep 2002 |
US |
|
60404233 |
Aug 2002 |
US |
|
60384445 |
May 2002 |
US |
|
60379562 |
May 2002 |
US |
|
60374229 |
Apr 2002 |
US |
|
60372679 |
Apr 2002 |
US |
|
60368776 |
Mar 2002 |
US |
|
60363685 |
Mar 2002 |
US |
|
60356994 |
Feb 2002 |
US |
|
60344953 |
Dec 2001 |
US |
|
60331948 |
Nov 2001 |
US |